Alcohol septal ablation for hypertrophic cardiomyopathy: Indications and technique
暂无分享,去创建一个
[1] S. Qiao,et al. [Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy]. , 2006, Zhonghua nei ke za zhi.
[2] S. Nagueh,et al. Predictors of Outcome After Alcohol Septal Ablation Therapy in Patients With Hypertrophic Obstructive Cardiomyopathy , 2004, Circulation.
[3] T. Cheng,et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy; The Chinese experience in 119 patients from a single center. , 2004, International journal of cardiology.
[4] A. van Rossum,et al. Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. , 2004, Journal of the American College of Cardiology.
[5] P. Boekstegers,et al. Catheter-based therapy for hypertrophic obstructive cardiomyopathy. First in-hospital outcome analysis of the German TASH Registry. , 2004, Zeitschrift fur Kardiologie.
[6] P. Seggewiss,et al. Catheter-based therapy for hypertrophic obstructive cardiomyopathy , 2004, Zeitschrift für Kardiologie.
[7] Barry J Maron,et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, Journal of the American College of Cardiology.
[8] Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. , 2003, Journal of the American College of Cardiology.
[9] J. Ross,et al. Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: early and intermediate results of a Canadian referral centre. , 2003, The Canadian journal of cardiology.
[10] W. Spencer,et al. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: Short‐term results in 50 consecutive procedures , 2003, Clinical Cardiology.
[11] J. Veselka,et al. Early remodelling of left ventricle and improvement of myocardial performance in patients after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. , 2003, International journal of cardiology.
[12] D. Fassbender,et al. [Predicting the risk of atrioventricular conduction lesions after percutaneous septal ablation for obstructive hypertrophic cardiomyopathy]. , 2003, Zeitschrift fur Kardiologie.
[13] U. Gleichmann,et al. Vorhersage des Risikos permanenter atrioventrikulärer Überleitungsstörungen nach perkutaner Septumablation bei Patienten mit hypertropher obstruktiver Kardiomyopathie , 2003, Zeitschrift für Kardiologie.
[14] S. Ommen,et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. , 2001, Journal of the American College of Cardiology.
[15] J. Plana,et al. Efficacy of nonsurgical septal reduction therapy in symptomatic patients with obstructive hypertrophic cardiomyopathy and provocable gradients. , 2001, The American journal of cardiology.
[16] W. Edwards,et al. Anatomy of the first septal perforating artery: a study with implications for ablation therapy for hypertrophic cardiomyopathy. , 2001, Mayo Clinic proceedings.
[17] S. Nagueh,et al. Regression of Left Ventricular Hypertrophy After Nonsurgical Septal Reduction Therapy for Hypertrophic Obstructive Cardiomyopathy , 2001, Circulation.
[18] L. Faber,et al. Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring. , 2000, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[19] H. Kuhn. [Transcoronary ablation of septal hypertrophy (TASH): a 5-year experience]. , 2000, Zeitschrift fur Kardiologie.
[20] H. Kuhn. Fünf Jahre TASH (Transkoronare Ablation der Septum Hypertrophie), eine Bilanz , 2000, Zeitschrift für Kardiologie.
[21] H. Seggewiss. Percutaneous transluminal septal myocardial ablation: a new treatment for hypertrophic obstructive cardiomyopathy. , 2000, European heart journal.
[22] L. Faber,et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients , 2000, Heart.
[23] M. Quiñones,et al. Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. , 1999, Journal of the American College of Cardiology.
[24] U. Gleichmann,et al. Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: Detection of threatening myocardial necrosis distant from the septal target area , 1999, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[25] U. Gleichmann,et al. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. , 1999, The Thoracic and cardiovascular surgeon.
[26] U. Gleichmann,et al. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. , 1998, Circulation.
[27] M. Verani,et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. , 1998, Circulation.
[28] M. Verani,et al. Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. , 1998, Journal of the American College of Cardiology.
[29] U. Sigwart. Non-surgical myocardial ablation: for hypertrophic obstructive cardiomyopathy. , 1998, Cardiologia.
[30] D. Fassbender,et al. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. , 1998, Journal of the American College of Cardiology.
[31] D. Harrington,et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. , 1997, Circulation.
[32] A. Tajik,et al. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. , 1996, Circulation.
[33] U. Sigwart. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy , 1995, The Lancet.
[34] J. Seward,et al. Hypertrophic obstructive cardiomyopathy: ten- to 21-year follow-up after partial septal myectomy. , 1983, The American journal of cardiology.
[35] W. Henry,et al. Operative Treatment in Hypertrophic Subaortic Stenosis: Techniques, and the Results of Pre and Postoperative Assessments in 83 Patients , 1975, Circulation.
[36] W. Weidman,et al. Idiopathic hypertrophic subaortic stenosis. Long-term surgical follow-up. , 1978 .
[37] J. Ross,et al. Obstruction to left ventricular outflow. Current concepts of management and operative treatment. , 1968, Annals of internal medicine.